PatientsPharma News

Diabetes, weight loss drugs drive growth for Novo and Lilly despite shortages

Novo Nordisk (NVO) and Eli Lilly (LLY) stocks were both boosted by sales of their Type 2 diabetes and weight loss drugs in the third quarter, despite shortages of supply of the three popular products — Novo’s Type 2 diabetes drug Ozempic, its weight loss drug Wegovy, and Lilly’s Type 2 drug Mounjaro — the companies announced Thursday.

The three drugs have seen a spike in popularity this year due to the unprecedented total body weight loss they provide compared to older GLP-1s — drugs that mimic a hormone in the body that slows digestion and promotes insulin production.

Continue reading @ Yahoo Finance…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button